Dermapharm Holding SE (DMP.DE)

EUR 38.15

(0.39%)

Revenue Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual revenue in 2023 was 1.13 Billion EUR , up 10.79% from previous year.
Dermapharm Holding SE's latest quarterly revenue in 2024 Q2 was 279.8 Million EUR , down -6.32% from previous quarter.
Dermapharm Holding SE reported a annual revenue of 1.02 Billion EUR in annual revenue 2022, up 8.68% from previous year.
Dermapharm Holding SE reported a annual revenue of 942.91 Million EUR in annual revenue 2021, up 18.78% from previous year.
Dermapharm Holding SE reported a quarterly revenue of 298.69 Million EUR for 2024 Q1, up 11.12% from previous quarter.
Dermapharm Holding SE reported a quarterly revenue of 284.46 Million EUR for 2023 Q3, up 8.17% from previous quarter.

Annual Revenue Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual Revenue of Dermapharm Holding SE (2023 - 2014)

Year	Revenue	Revenue Growth
2023	1.13 Billion EUR	10.79%
2022	1.02 Billion EUR	8.68%
2021	942.91 Million EUR	18.78%
2020	793.82 Million EUR	13.26%
2019	700.87 Million EUR	22.44%
2018	572.42 Million EUR	22.54%
2017	467.11 Million EUR	5.09%
2016	444.47 Million EUR	15.5%
2015	384.84 Million EUR	-1.66%
2014	391.34 Million EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	279.8 Million EUR	-6.32%
2024 Q1	298.69 Million EUR	11.12%
2023 Q3	284.46 Million EUR	8.17%
2023 Q4	268.79 Million EUR	-5.51%
2023 FY	1.13 Billion EUR	10.79%
2023 Q1	319.11 Million EUR	9.84%
2023 Q2	262.96 Million EUR	-17.6%
2022 Q1	231.64 Million EUR	-15.06%
2022 FY	1.02 Billion EUR	8.68%
2022 Q2	239.47 Million EUR	3.38%
2022 Q4	290.51 Million EUR	10.4%
2022 Q3	263.13 Million EUR	9.88%
2021 Q4	272.71 Million EUR	12.49%
2021 FY	942.91 Million EUR	18.78%
2021 Q2	215.53 Million EUR	1.57%
2021 Q3	242.44 Million EUR	12.48%
2021 Q1	212.21 Million EUR	-2.05%
2020 Q4	216.65 Million EUR	8.88%
2020 FY	793.82 Million EUR	13.26%
2020 Q3	198.97 Million EUR	7.13%
2020 Q2	185.72 Million EUR	-3.5%
2020 Q1	192.46 Million EUR	5.0%
2019 Q2	169.61 Million EUR	3.71%
2019 FY	700.87 Million EUR	22.44%
2019 Q1	163.55 Million EUR	14.0%
2019 Q4	183.3 Million EUR	-0.6%
2019 Q3	184.4 Million EUR	8.72%
2018 Q4	143.46 Million EUR	-3.52%
2018 FY	572.42 Million EUR	22.54%
2018 Q2	142.76 Million EUR	3.83%
2018 Q1	137.49 Million EUR	17.09%
2018 Q3	148.7 Million EUR	4.16%
2017 Q2	116.15 Million EUR	-1.63%
2017 Q3	115.46 Million EUR	-0.59%
2017 Q1	118.07 Million EUR	-5.74%
2017 FY	467.11 Million EUR	5.09%
2017 Q4	117.42 Million EUR	1.7%
2016 FY	444.47 Million EUR	15.5%
2016 Q4	125.25 Million EUR	0.0%
2015 FY	384.84 Million EUR	-1.66%
2014 FY	391.34 Million EUR	0.0%

Peer Revenue Comparison of Dermapharm Holding SE

Name	Revenue	Revenue Difference
MPH Health Care AG	34.43 Million EUR	-3197.515%
Apontis Pharma AG	36.96 Million EUR	-2971.522%
Evotec SE	781.42 Million EUR	-45.292%
MERCK Kommanditgesellschaft auf Aktien	20.99 Billion EUR	94.592%
PharmaSGP Holding SE	101.09 Million EUR	-1023.009%
SynBiotic SE	3.86 Million EUR	-29302.909%